Health

The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant – DocWire News

Transplantation. 2021 Nov 9. doi: 10.1097/TP.0000000000003983. Online ahead of print.ABSTRACTBACKGROUND: In kidney patients COVID-19…

Published

4 years ago

November 10, 2021

Noosa Online News Publisher

Transplantation. 2021 Nov 9. doi: 10.1097/TP.0000000000003983. Online ahead of print.
ABSTRACT
BACKGROUND: In kidney patients COVID-19 is associated with severely increased morbidity and mortality. A comprehensive comparison of the immunogenicity, tolerability,…

Click here to view the original article.

Related Topics:Australia Docwirenews.com Featured

Up Next

Geelong Covid cases: Covenant College closes; 11 new infections – Geelong Advertiser

Don't Miss

Immunologist Dr. Anthony Leonardi speaks on Long COVID and the dangers posed by SARS-CoV-2 – WSWS

Noosa News24 hours ago

‘Just want to know he’s safe’: Family’s German Shepherd asleep in back of stolen ute

Noosa News24 hours ago

Driver acquitted of murder over lengthy road-rage chase

General22 hours ago

Mitchell Starc fires Ashes warning in Sheffield Shield return as Jake Weatherald and Beau Webster fail to fire

General23 hours ago

Nampijinpa Price pulls out of Put Australia First rally appearance with far-right activist Tommy Robinson

Noosa Online News

The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant – DocWire News

Trending